ObjectiveTo analyze the effects of neoactivin pre-application on cardiac function, NT-ProBNP level, myocardial microcirculation and adverse cardiac events in patients with acute myocardial infarction after emergency percutaneous coronary intervention (PCI).
MethodsA total of 88 patients hospitalized from 2020 to 2021 were selected as the study objects, and randomly divided into the observation group (43 cases) and the control group (45 cases).All patients were treated with emergency PCI.The patients in the observation group were immediately treated with neoactivin on the basis of standard drug treatment after diagnosis, while the control group was not treated with neoactivin.The cardiac function, the level of NT-ProBNP, myocardial microcirculation and the occurrence of adverse events were observed and compared between the two groups.
ResultsThe heart function of the observation group patients was better than that of the control group, with a higher left ventricular ejection fraction, lower left ventricular end diastolic volume, and lower left ventricular end diastolic diameter compared to the control group (P < 0.01).The level of NT-ProBNP in the observation group was lower than that in the control group (P < 0.01).The thrombolytic blood flow grading of myocardial infarction in the observation group was higher than that in the control group (P < 0.01), and the frame count value was lower than that in the control group (P < 0.01).The incidence of adverse events such as myocardial infarction, malignant arrhythmia, heart failure and sudden cardiac death in the observation group was significantly lower than that in the control group (P < 0.05).
ConclusionsPre-application of neoactivin in emergency PCI patients with acute myocardial infarction can significantly improve cardiac function, reduce the level of NT-ProBNP, improve myocardial microcirculation and reduce the occurrence of adverse cardiac events.
DownLoad: